Search - tctmd.com

Displaying 761 - 780 of 1012

Sort: Relevancy | Date

Presentation TCT 2014

A Golden Year for TAVR - Accomplishments, Controversies, and Future Directions

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, Martin B. Leon

September 16, 2014

Presentation TCT 2014

Clinical Indications for TAVR: Where are We and Where are We Going?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, A. Pieter Kappetein

September 16, 2014

Presentation TCT 2014

Cases #2 and #3: Essentials of One-Stent and Two-Stent Technique Optimization

Presenter: Shao Liang Chen, Issam D. Moussa, Leif Thuesen, Michael Maeng

September 16, 2014

Presentation TCT 2014

Cases #1 and #2: Overcoming Difficult Radial Access

Presenter: Mauricio G. Cohen, Samir B. Pancholy, Tejas Patel, Michael A. Kutcher

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

Presentation TCT 2014

Fundamentals for Creating of a Successful Multidisciplinary LAA Occlusion Program

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Michael J. Rinaldi

September 15, 2014

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

Reversal of Factor Xa Inhibition

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Lisa K. Jennings

September 15, 2014

Presentation TCT 2014

TCT 269: Drug-Coated Balloon vs Standard Balloon for the PTA Treatment of Lesions in the SFA and Popliteal Artery? First Interim Results of the FREERIDE Study

Presenter: Peter A. Schneider, Gunnar Tepe, Michael H. Wholey, Schulte Karl-Ludwig, MD

September 15, 2014

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

TCT 532: Economic Outcomes of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons vs Standard PTA: 1-Year Results from the IN.PACT SFA II Trial

Presenter: Peter A. Schneider, Gunnar Tepe, Michael H. Wholey, Adam Salisbury, MD

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff

September 15, 2014

Presentation TCT 2014

Con: Ignore Aortic Regurgitation at Your Own Risk!

Presenter: Simon Redwood, Michael J. Mack

September 15, 2014

Presentation TCT 2014

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Presenter: Matthew J. Price, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Advertisement

A Golden Year for TAVR - Accomplishments, Controversies, and Future Directions

Clinical Indications for TAVR: Where are We and Where are We Going?

Cases #2 and #3: Essentials of One-Stent and Two-Stent Technique Optimization

Cases #1 and #2: Overcoming Difficult Radial Access

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Fundamentals for Creating of a Successful Multidisciplinary LAA Occlusion Program

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Reversal of Factor Xa Inhibition

TCT 269: Drug-Coated Balloon vs Standard Balloon for the PTA Treatment of Lesions in the SFA and Popliteal Artery? First Interim Results of the FREERIDE Study

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

TCT 532: Economic Outcomes of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons vs Standard PTA: 1-Year Results from the IN.PACT SFA II Trial

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Con: Ignore Aortic Regurgitation at Your Own Risk!

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content